Recro Pharma Inc said an intravenous version of its lead painkiller was successful in the first of two pivotal late-stage trials, sending the company’s shares surging 50 percent in trading after the bell.
The drug, Meloxicam, was being evaluated to treat acute pain in patients after a bunionectomy surgery, which involves removing or realigning soft tissue and bones in the joint of the big toe.
Meloxicam is a non-opioid drug, a class of drugs that do not have the side effects associated with commonly prescribed opioid drugs. These effects include addiction, constipation and respiratory distress.
Filed under: Uncategorized |